重点通报！戏比家强？吴京拍戏一年半没回家，谢楠坦言不易：理解并支持

戏比家强？吴京拍戏一年半没回家，谢楠坦言不易：理解并支持

北京 - 知名演员吴京以其硬汉形象和精湛的演技深受观众喜爱，然而鲜为人知的是，为了拍戏，他曾长达一年半没有回家。近日，吴京的妻子谢楠在某节目中谈及此事，坦言理解并支持丈夫的付出。

谢楠表示，吴京拍戏向来认真敬业，为了呈现最好的效果，他经常不辞辛苦，全身心投入到工作中。有一次，吴京为了拍摄一部电影，在剧组待了整整14个月，期间几乎没有回家看过一次家人。

长期的分离难免会带来一些问题。谢楠坦言，她也曾因为吴京长时间不在家而感到失落和孤独，但最终她选择理解和支持丈夫的决定。她说：“我知道他是在做自己喜欢的事，为了自己的梦想而努力奋斗，所以我应该支持他。”

吴京和谢楠的婚姻一直备受外界关注，他们相识多年，感情深厚。尽管工作繁忙，吴京也总是会尽量抽出时间陪伴家人。谢楠曾在微博上晒出吴京为孩子们做饭的照片，画面温馨感人。

吴京的敬业精神和谢楠的理解与支持，也感动了许多网友。有网友评论道：“吴京真的是一位好演员，为了拍戏付出了很多。他的妻子也很贤惠，能够理解和支持他。”

吴京和谢楠的经历也告诉我们，经营一段婚姻需要双方的共同努力和理解。在追求梦想的同时，也要兼顾家庭，只有夫妻同心协力，才能收获幸福美满的生活。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.